However, since the presence of “ready-to-act” CD4+CD44+Ly6C+ T-effector cells requires a persistent infection of Leishmania parasites, achieving durable protection through safer vaccination methods makes TRM populations more desirable to target. This evidence concerns the gene CD44 and infection.